Back to Search
Start Over
Alexza Pharmaceuticals Inc resubmits AZ-004 NDA for treatment in schizophrenia or bipolar disorder patients
- Source :
- M2 Communications. August 8, 2011
- Publication Year :
- 2011
-
Abstract
- Aug 08, 2011 (M2 EQUITYBITES via COMTEX) -- Pharmaceutical company Alexza Pharmaceuticals Inc (Nasdaq:ALXA) revealed on Friday the resubmission of its AZ-004 New Drug Application (NDA) to the US Food [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- M2 Communications
- Publication Type :
- News
- Accession number :
- edsgcl.263644770